3
Announcements
Trials
Browse
Landscape
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
21
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
20
Carcinoma, Renal Cell
16
Liver Neoplasms
7
Leukemia, Myeloid, Acute
3
Thyroid Neoplasms
2
Financial Stress
2
Carcinoma
2
Patient Preference
1
Neuroendocrine Tumors
1
Neoplastic Cells, Circulating
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies
1
Carcinoma, Non-Small-Cell Lung
1
COVID-19
1
Adenoma, Islet Cell
1
Interventions
Gene Expression Profiling
9
Blood Specimen Collection
6
Polymerase Chain Reaction
5
Immunohistochemistry
5
Amplified Fragment Length Polymorphism Analysis
5
Surveys and Questionnaires
3
Sunitinib
3
Reverse Transcriptase Polymerase Chain Reaction
3
Flow Cytometry
3
Biopsy
3
Surgical Procedures, Operative
2
Radiotherapy
2
Radiosurgery
2
Patient Reported Outcome Measures
2
Observation
2
Nivolumab
2
Microarray Analysis
2
Immunotherapy
2
Genetic Testing
2
Drug Therapy
2
DNA Methylation
2
Cytogenetic Analysis
2
tremelimumab
1
pembrolizumab
1
durvalumab
1
atezolizumab
1
aldesleukin
1
X-Rays
1
Watchful Waiting
1
Tomography, Optical Coherence
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Kidney Neoplasms
×
Sorafenib
×
Clear all
NCT01230697
2010-10-29
SORHORM
University of Turin, Italy
Unknown
60 enrolled